PKI - PerkinElmer, Inc.

NYSE - NYSE Delayed Price. Currency in USD

PerkinElmer, Inc.

940 Winter Street
Waltham, MA 02451
United States
781-663-6900
http://www.perkinelmer.com

SectorHealthcare
IndustryDiagnostics & Research
Full Time Employees11,000

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert F. FrielChairman, CEO & Pres5.05M13.87M1956
Mr. Frank A. WilsonSr. VP & CFO1.59M2.56M1959
Mr. Joel S. GoldbergSr. VP of Admin., Gen. Counsel & Sec.1.36M2.1M1969
Mr. James CorbettExec. VP & Pres of Discovery and Analytical Solutions1.26M42.84k1963
Mr. Prahlad R. SinghExec. VP & Pres of Diagnostics852.93kN/A1965
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

Corporate Governance

PerkinElmer, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.